Smad3 deficiency inhibits v-ras-induced transformation by suppression of JNK MAPK signaling and increased farnesyl transferase inhibition

Oncogene

Volumn 27, Issue 17, 2008, Pages 2507-2512

  Arany, P R ^a,c   Rane, S G ^a,b,c   Roberts, A B ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

Farnesyl transferase inhibition; JNK MAPK; Malignant transformation; Ras; Smad3; TGF 1

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; SMAD3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CONTROLLED STUDY; EMBRYO; FIBROBLAST; GENE DELETION; GENE REPRESSION; GENETIC TRANSFORMATION; MOUSE; MOUSE EMBRYONIC FIBROBLAST; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN DEFICIENCY; SIGNAL TRANSDUCTION; SMAD3 PROTEIN DEFICIENCY;

ALKYL AND ARYL TRANSFERASES; ANIMALS; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; ONCOGENE PROTEIN P21(RAS); PHENOTYPE; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSGENES;

EID: 42049095152     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210889     Document Type: Article

References (44)

1. Arany PR, Flanders KC, Kobayashi T, Kuo CK, Stuelten C, Desai KV et al. (2006). Smad3 deficiency alters key structural elements of the extracellular matrix and mechanotransduction of wound closure. Proc Natl Acad Sci USA 103: 9250-9255.
2. Atfi A, Djelloul S, Chastre E, Davis R, Gespach C. (1997). Evidence for a role of Rho-like GTPases and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in transforming growth factor beta-mediated signaling. J Biol Chem 272: 1429-1432.
3. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S et al. (2004). TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303: 848-851.
4. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME et al. (2001). Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 12: 27-36.
5. Blobe GC, Schiemann WP, Lodish HF. (2000). Role of transforming growth factor beta in human disease. N Engl J Med 342: 1350-1358.
6. Bost F, McKay R, Bost M, Potapova O, Dean NM, Mercola D. (1999). The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells. Mol Cell Biol 19: 1938-1949.
7. Brassard DL, English JM, Malkowski M, Kirschmeier P, Nagabhushan TL, Bishop WR. (2002). Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras. Exp Cell Res 273: 138-146.
8. Byfield SD, Roberts AB. (2004). Lateral signaling enhances TGF-beta response complexity. Trends Cell Biol 14: 107-111.
9. Cox AD, Garcia AM, Westwick JK, Kowalczyk JJ, Lewis MD, Brenner DA et al. (1994). The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation. J Biol Chem 269: 19203-19206.
10. Cox AD, Hisaka MM, Buss JE, Der CJ. (1992). Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein. Mol Cell Biol 12: 2606-2615.
11. Egeblad M, Littlepage LE, Werb Z. (2005). The fibroblastic coconspirator in cancer progression. Cold Spring Harb Symp Quant Biol 70: 383-388.
12. Filmus J, Zhao J, Buick RN. (1992). Overexpression of H-ras oncogene induces resistance to the growth-inhibitory action of transforming growth factor beta-1 (TGF-beta 1) and alters the number and type of TGF-beta 1 receptors in rat intestinal epithelial cell clones. Oncogene 7: 521-526.
13. Fong LG, Frost D, Meta M, Qiao X, Yang SH, Coffinier C et al. (2006). A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science 311: 1621-1623.
14. Hayashida T, Decaestecker M, Schnaper HW. (2003). Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-beta-dependent responses in human mesangial cells. FASEB J 17: 1576-1578.
15. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ. (1992). Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 89: 6403-6407.
16. Kennedy NJ, Sluss HK, Jones SN, Bar-Sagi D, Flavell RA, Davis RJ. (2003). Suppression of Ras-stimulated transformation by the JNK signal transduction pathway. Genes Dev 17: 629-637.
17. Kim SJ, Angel P, Lafyatis R, Hattori K, Kim KY, Sporn MB et al. (1990). Autoinduction of transforming growth factor beta 1 is mediated by the AP-1 complex. Mol Cell Biol 10: 1492-1497.
18. Kretzschmar M, Doody J, Timokhina I, Massague J. (1999). A mechanism of repression of TGF-beta/Smad signaling by oncogenic Ras. Genes Dev 13: 804-816.
19. Laping NJ, Everitt JI, Frazier KS, Burgert M, Portis MJ, Cadacio C et al. (2007). Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats. Clin Cancer Res 13: 3087-3099.
20. Lebowitz PF, Prendergast GC. (1998). Non-Ras targets of farnesyl-transferase inhibitors: focus on Rho. Oncogene 17: 1439-1445.
21. Lehmann K, Janda E, Pierreux CE, Rytomaa M, Schulze A, McMahon M et al. (2000). Raf induces TGF-beta production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. Genes Dev 14: 2610-2622.
22. Massague J, Gomis RR. (2006). The logic of TGF-beta signaling. FEBS Lett 580: 2811-2820.
23. Massague J. (1992). Receptors for the TGF-beta family. Cell 69: 1067-1070.
24. Matsuura I, Wang G, He D, Liu F. (2005). Identification and characterization of ERK MAP kinase phosphorylation sites in Smad3. Biochemistry 44: 12546-12553.
25. Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E. (1996). TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 10: 2462-2477.
26. Park BJ, Park JI, Byun DS, Park JH, Chi SG. (2000). Mitogenic conversion of transforming growth factor-beta1 effect by oncogenic Ha-Ras-induced activation of the mitogen-activated protein kinase signaling pathway in human prostate cancer. Cancer Res 60: 3031-3038.
27. Piek E, Ju WJ, Heyer J, Escalante-Alcalde D, Stewart CL, Weinstein M et al. (2001). Functional characterization of transforming growth factor beta signaling in Smad2- and Smad3-deficient fibroblasts. J Biol Chem 276: 19945-19953.
28. Prendergast GC, Davide JP, deSolms SJ, Giuliani EA, Graham SL, Gibbs JB et al. (1994). Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol Cell Biol 14: 4193-4202.
29. Prendergast GC. (2001). Actin' up: RhoB in cancer and apoptosis. Nat Rev Cancer 1: 162-168.
30. Radisky DC, Kenny PA, Bissell MJ. (2007). Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT? J Cell Biochem 70: 830-839.
31. Roberts AB, Wakefield LM. (2003). The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 100: 8621-8623.
32. Roberts AB, Lamb LC, Newton DL, Sporn MB, De Larco JE, Todaro GJ. (1980). Transforming growth factors: isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extraction. Proc Natl Acad Sci USA 77: 3494-3498.
33. Roop DR, Lowy DR, Tambourin PE, Strickland J, Harper JR, Balaschak M et al. (1986). An activated Harvey ras oncogene produces benign tumours on mouse epidermal tissue. Nature 323: 822-824.
34. Saha D, Datta PK, Beauchamp RD. (2001). Oncogenic ras represses transforming growth factor-beta/Smad signaling by degrading tumor suppressor Smad4. J Biol Chem 276: 29531-29537.
35. Santibanez JF, Olivares D, Guerrero J, Martinez J. (2003). Cyclic AMP inhibits TGFbeta1-induced cell-scattering and invasiveness in murine-transformed keratinocytes. Int J Cancer 107: 715-720.
36. Santibanez JF, Quintanilla M, Martinez J. (2002). TGF-beta(1) and Smad4 overexpression induce a less invasive phenotype in highly invasive spindle carcinoma cells. FEBS Lett 520: 171-176.
37. Sekimoto G, Matsuzaki K, Yoshida K, Mori S, Murata M, Seki T et al. (2007). Reversible Smad-dependent signaling between tumor suppression and oncogenesis. Cancer Res 67: 5090-5096.
38. ten Dijke P, Franzen P, Yamashita H, Ichijo H, Heldin CH, Miyazono K. (1994). Serine/threonine kinase receptors. Prog Growth Factor Res 5: 55-72.
39. Ventura JJ, Kennedy NJ, Flavell RA, Davis RJ. (2004). JNK regulates autocrine expression of TGF-beta1. Mol Cell 15: 269-278.
40. Vijayachandra K, Lee J, Glick AB. (2003). Smad3 regulates senescence and malignant conversion in a mouse multistage skin carcinogenesis model. Cancer Res 63: 3447-3452.
41. Wisdom R, Huynh L, Hsia D, Kim S. (2005). RAS and TGF-beta exert antagonistic effects on extracellular matrix gene expression and fibroblast transformation. Oncogene 24: 7043-7054.
42. Yamagata H, Matsuzaki K, Mori S, Yoshida K, Tahashi Y, Furukawa F et al. (2005). Acceleration of Smad2 and Smad3 phosphorylation via c-Jun NH(2)-terminal kinase during human colorectal carcinogenesis. Cancer Res 65: 157-165.
43. Yoshida K, Matsuzaki K, Mori S, Tahashi Y, Yamagata H, Furukawa F et al. (2005). Transforming growth factor-beta and platelet-derived growth factor signal via c-Jun N-terminal kinase-dependent Smad2/3 phosphorylation in rat hepatic stellate cells after acute liver injury. Am J Pathol 166: 1029-1039.
44. Yue J, Mulder KM. (2001). Transforming growth factor-beta signal transduction in epithelial cells. Pharmacol Ther 91: 1-34.